Strategic Project & Portfolio Management for Pharma

More Information

20th Annual

Strategic Project & Portfolio Management for Pharma

27 - 29 January 2021

Live Streaming and On-Demand

What do you hope to learn from others by attending the event?

What I have found over the many years that I have been attending PPM conferences is that there are always nuggets of information and insights that you pick-up and sometimes in the most unexpected presentations.

What is the biggest challenge in project management in a world redefined by Covid 19 world?

From speaking with PPM professionals from across the pharma and biotech industries in my role as an executive committee member of the pharmaceutical industry project management group (PIPMG), the biggest challenge that I discern in the Covid 19 redefined project management world is figuring out how best to deal with the negative impact that working exclusively in a virtual team environment for sustained periods of time is having on project team performance.

How do you define project management maturity and why do you think it is important?

Maturity refers to a person or thing becoming fully grown or developed or to reaching a desired future state and the concept of project management maturity is concerned with identifying how well-developed project management capability is within an organization. Project management maturity is important because organizations that are highly mature in their capabilities outperform those that are not, and higher maturity levels go hand in hand with higher levels of project performance.

What do you think is the key to advancing project management maturity?

The most important keys to advancing project management maturity within an organization in my view, are to understand the current state of maturity, to clearly identify the areas that would most benefit from capability improvement, to determine the steps needed to improve these capabilities and to successfully implement a capability improvement plan.

An interview with:

Tom Halliwell, Director, Global Program Leader Oncology at Ipsen Biopharm Ltd.

Follow us on Social Media!

With increased impact from the pandemic, pharma and biotech companies are under pressure to deliver results and adapt to new business realities with a fresh approach to PPM. Covid-19 and its aftermath have brought into focus the need to prioritize better and deliver results under increased budget constraints. Project selection and portfolio valuation are crucial tools for PPM managers to understand their competitive advantage, core portfolio values and market forecasts, and to align with their strategic corporate objectives.

This marcus evans unique conference will discuss how you can articulate your priorities better in a COVID-19 environment, and how to overcome increased reporting overload and drive a positive impact in your portfolio strategy. We will explore strategic modeling in times of uncertainty, and how to align R&D and Commercial with an integrated data strategy that takes advantage of AI and machine learning opportunities. By attending this event, you will learn how to do efficient scenario prediction to achieve the right risk-benefit balance in your portfolio, and how in the long run, you can adapt to the new normal with resilient portfolio performance informed by sound-decision making.

Your safety is our top priority.

Can’t physically attend this conference?

Don’t worry we have you covered! If your ability to travel is restricted we know your appetite for key business insights remains so our Live+ digital platform enables you to fully participate in the event remotely. Of course it provides access to live online streams of all session, but much more than that, it ensures you are able to engage with speakers directly allowing you to participate in Q&A, relevant breakout groups as well as event polling and other insights and resources delivered during the event. We realise interacting with other delegates is key to your event experience, so our innovate online solution allows you to set up online meetings with other virtual and physical attendees throughout the event; ensuring you still walk away with those key contacts that can make a tangible difference to you and your business. The platform will continue to host all event content on-demand for you to re-visit and continue to access for up to 6 months post event.

Your content. Your way.

About the conference

We would be delighted to provide you with more information on the conference agenda. Please fill in your details below and we will be in touch.

Tom has over 30 years’ experience in the Pharmaceutical and Diagnostic’s industries. Tom started his industry career in diagnostics at Amersham International (now GE Healthcare) and then Anagen (now Alfa Sigma). Tom transitioned to Pharmaceuticals in 1996 and spent fifteen years at Roche in a variety of positions including Avastin Franchise Global Project Manager and UK Project Management Group Site Head. Tom joined Norgine in 2011 where he became a Therapy Area Director and in July 2018, he joined Ipsen as Global Program Leader Oncology. Tom has been responsible for the development and launch of several diagnostic products as Project Leader (Amerlite anti-HBs and HAV IgM), a number of medicinal products as Global Project Manager (Herceptin, Avastin and Bondronat) and the successful registration and launch of MUGARD (medical device), MOVICOL Ready to Take and LYMPHOSEEK as Therapy Area Director. Tom is a Fellow of the Institute of Biomedical Sciences, a member of AMBA and an Executive Committee member of the Pharmaceutical Industry Project Management Group (formerly Chairman).

To view the Conference Agenda, click HERE!

For all enquiries regarding speaking, sponsoring and attending this conference contact:

Yiota Andreou
Email: Yiotaa@marcusevanscy.com
Telephone: +357 22849 404
Fax: +357 22 849 394